Skip to main content
. 2022 May 10;57(8):1250–1259. doi: 10.1038/s41409-022-01698-3

Fig. 5. FasL AM treatment of MPBCs attenuates acute GvHD in a xenogeneic GvHD model, enhances the short-term engraftment of human cells and does not impair re-constitution potential of HSPC in mice 4 weeks post administration.

Fig. 5

GvHD score (a, c) and percent survival (b, d) of two independent experiments in γ-irradiated NSG mice transplanted with either 100 ng/ml FasL AM treated or untreated MPBCs control grafts. a, b Experiment 1: MPBCs + FasL AM and MPBCs N = 8 mice/group, Vehicle N = 2 mice/group; c, d Experiment 2: MPBCs + FasL AM and MPBCs N = 10 mice/group, Vehicle N = 3 mice/group; Mean ± SEM, Multiple T tests; Kaplan–Maier survival curve, Log-rank (Mantel–Cox) test; *P ≤ 0.05, **P ≤ 0.01. e–h Engraftment of human cells in the bone marrow of treated mice, 4 weeks post-transplantation. The absolute cell numbers of (e) human CD45+and (f) human CD34+, (g) percentage of CD34+ per total BM cells (BM) population; MPBCs+FasL AM N = 10, MPBCs N = 6. h CFU capacity of BMC derived from mice and cultured for 2 weeks for colony growth. MPBCs + FasL AM N = 8, MPBCs N = 3. e–h Each data point represents an individual mouse, horizontal lines represent the median of each treatment group *P ≤ 0.05, Mann–Whitney test.